# Mesoblast Limited share price today (Mesoblast Limited, MESO)

> Mesoblast Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. MESO · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/meso

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $14.10 (−3.5% in a year)
- Revenue (Jun 2026): $68.9 M (+390.7% on a year ago)
- Profit (Jun 2026): −$17.3 M
- Operating margin: −33.3% (+269.1 points on a year ago)
- ROE: −10%, FY26
- ROIC: −4.5%, against a 9.2% cost of capital: −13.7 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Mesoblast Limited share price today? Mesoblast Limited's share price was $14.10 at the close on 5 November 2026. It has been falling for 3 weeks. That is 8.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $12 and $21, and at that close it sat 21% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 10 years the share price moved +71% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Mesoblast Limited pay? Mesoblast Limited pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Mesoblast Limited on? Mesoblast Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Mesoblast Limited profitable? Mesoblast Limited posted a net loss of $17.3 M in the Jun 2026 quarter. The full FY26 year was a loss of $57.5 M. That loss is 25.2% of the quarter's revenue. The same quarter a year earlier lost $55.4 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Mesoblast Limited make, and is it growing? Mesoblast Limited reported $68.9 M of revenue in the Jun 2026 quarter, +390.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 5 years it has grown 74.5% a year on average. The last full year, FY26, came in at $120 M. FY26 revenue was $120 M, +599.2% on the year before. Recent pace: the last four quarters grew +592.3% on average, against 74.5% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +925.5%, against +179.1% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Mesoblast Limited keep? Mesoblast Limited's operating margin was −33.3% in the Jun 2026 quarter, 269.1 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved +1,215.2 percentage points. Across 6 years it has been between −1,196.1% and −42.6%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +1,215.2 percentage points on the year while gross margin changed +1,310.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Mesoblast Limited's profit turning into cash? Mesoblast Limited's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used $43.8 M of cash, against −$57.5 M of profit. After $833 K of spending on assets, free cash was −$44.7 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Mesoblast Limited's cash go? Mesoblast Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.8 M on assets over the last 3 years. Averaged over those years that is 0.5% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.8 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Mesoblast Limited's P/E ratio, and how does it compare with its own history? Mesoblast Limited has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Mesoblast Limited at 16.3× its FY26 revenue of $120 M. The P/E comes back here once profit turns positive. ## Is the Mesoblast Limited business getting better or worse? Mesoblast Limited's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Mesoblast Limited earn on its capital? Mesoblast Limited earned a ROE of −10% in FY26. That is up from a low of −18% in FY22. Its return on capital used (ROIC) is 13.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −47.8% net margin and 0.16× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −47.8% net margin × 0.16× asset turnover × 1.36× leverage (assets divided by equity) ≈ −10.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −4.5% − 9.2% = −13.7 percentage points. The 9.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −4.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY21 at −16.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Mesoblast Limited have too much debt? Mesoblast Limited has total debt of $127 M against shareholder equity of $568 M as of Jun 2026, so its debt is 0.22× its equity, which is very little. Year by year, that ratio went from 0.18 in FY21 to 0.22 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Mesoblast Limited shareholding pattern? We have no ownership or short-position figures for Mesoblast Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 14.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Mesoblast Limited from balance-sheet trouble? For Mesoblast Limited, the Z-score is 4.13. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.13 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Mesoblast Limited rank in its industry? There is no score against its industry: Mesoblast Limited is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Mesoblast Limited compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Mesoblast Limited in size? Mesoblast Limited is the 77th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Immunome, Inc., Zymeworks Inc. and Fortrea Holdings Inc. Just below it: Harmony Biosciences Holdings, Inc., Vir Biotechnology, Inc. and Sarepta Therapeutics, Inc. ### Biotechnology companies close in size

1. [Immunome, Inc.](https://www.sectoralpha.in/us/stocks/imnm) $2.1 billion
2. [Zymeworks Inc.](https://www.sectoralpha.in/us/stocks/zyme) $2 billion
3. [Fortrea Holdings Inc.](https://www.sectoralpha.in/us/stocks/ftre) $2 billion
4. Mesoblast Limited $2 billion
5. [Harmony Biosciences Holdings, Inc.](https://www.sectoralpha.in/us/stocks/hrmy) $1.9 billion
6. [Vir Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/vir) $1.9 billion
7. [Sarepta Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/srpt) $1.9 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Denison Mines Corp.](https://www.sectoralpha.in/us/stocks/dnn) $1.9 billion · Uranium
2. [Dime Commercial Bancshares, Inc.](https://www.sectoralpha.in/us/stocks/dcom) $1.9 billion · Banks - Regional
3. Mesoblast Limited $1.9 billion
4. [German American Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/gabc) $1.9 billion · Banks - Regional
5. [OceanFirst Financial Corp.](https://www.sectoralpha.in/us/stocks/ocfc) $1.9 billion · Banks - Regional

## What else do people ask about Mesoblast Limited? ### What is Mesoblast Limited Limited's stock price today? Mesoblast Limited's stock price is $14.10, −3.5% over the past year. The whole company is worth $2.0 B on the market. In the last 52 weeks it traded between $12 to $21; today it is 21% of the way up from the low, 8.1% below its 200-day average (as of 5 November 2026). ### What were Mesoblast Limited Limited's latest quarterly results? Mesoblast Limited reported revenue of $68.9 M and a net loss of $17.3 M for the Jun 2026 quarter. Earnings per share were −$0.01. The operating margin was −33.3%, 269.1 percentage points higher than a year earlier (as of 5 November 2026). ### What is Mesoblast Limited Limited's market cap? Mesoblast Limited's market capitalisation is $2.0 B at a stock price of $14.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Mesoblast Limited Limited performing? Mesoblast Limited's share price has been falling for 3 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Mesoblast Limited Limited's stock price go up? This page does not forecast Mesoblast Limited's stock price. What it shows instead: the stock price is $14.10, and it has been falling for 3 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Where is Mesoblast Limited Limited in its business cycle? Mesoblast Limited's FY26 operating margin was −42.6%, against a 6-year range of −1,196.1% to −42.6%: the middle of its own range, neither a peak nor a low. The latest quarter was −33.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Mesoblast Limited Limited story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Mesoblast Limited Limited a stock worth studying right now? What the numbers show: Mesoblast Limited's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.